Stock 6576 FORESEE PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Foresee Pharmaceuticals Co., Ltd.

Equities

6576

TW0006576002

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
83.5 TWD 0.00% Intraday chart for Foresee Pharmaceuticals Co., Ltd. -15.14% -13.20%
24/06 Foresee Pharmaceuticals Co., Ltd. announced a financing transaction CI
14/05 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Foresee Pharmaceuticals Co., Ltd. Appoints Chris Liang as Accounting Officer
Foresee Pharmaceuticals Announces First Subject Dosed in Its First-In-Human Clinical Trial of FP-020
Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes, Effective March 31, 2024
Foresee Pharmaceuticals Co., Ltd. Obtains the Official Pharmaceutical License of CAMCEVI 42 Mg from the Ministry of Health and Welfare in Taiwan
Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Member to the Compensation Committee
Foresee Pharmaceuticals Co., Ltd. Appoints Ben Liu as Audit Committee Member
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Independent Director
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes
Foresee Pharmaceuticals Co., Ltd. Announces the Primary Endpoint Data FP-025 in an Allergic Asthma Phase 2A Trial
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6576 Stock
  4. News Foresee Pharmaceuticals Co., Ltd.
  5. Other languages